ScreenerHero

LTRN Lantern Pharma Inc.

NAS · US · Healthcare · Biotechnology · lanternpharma.com
0.9100USD-4.58%Mkt Cap: 13.59M $P/E: —

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small ce…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap13.59M USD
Enterprise Value4.87M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.12M USD
Revenue/Share—
Last Price0.9100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.47
PEG—
EV/EBITDA-0.32
EV/Revenue—
P/S—
P/B-3.78
EPS (TTM)-1.64
EPS (Forward)-2.02
52W Range
0.83752% of range4.703
52W High4.703 USD
52W Low0.8375 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-262.00%
ROA-155.13%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.68M USD
CapEx (TTM)1.72K USD
FCF Margin—
FCF Yield-60.59%
Net Debt-7.32M USD
Net Debt/EBITDA0.47
Balance Sheet
Debt/Equity0.01
Current Ratio1.96
Quick Ratio1.71
Book Value/Sh-0.25 USD
Cash/Share0.58 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)17.50 USD
Upside (mean)+1823.1%
Target Range10.00 USD – 25.00 USD
10.00+1823.1% to mean25.00
# Analysts2
Ownership
Shares Out.14.94M
Float9.85M
Insiders17.36%
Institutions19.31%
Short Interest
Short Ratio3.7d
Short % Float4.38%
Short % Out.4.36%
Shares Short557.98K
Short (prev mo.)693.03K
Technical
SMA 502.031 (-55.2%)
SMA 2002.711 (-66.4%)
Beta2.32
S&P 52W Chg16.45%
Avg Vol (30d)260.28K
Avg Vol (10d)398.16K
Technical Indicators
RSI (14)17.7
MACD-0.3526
MACD Signal-0.3544
MACD Hist.+0.0017
BB Upper2.008 USD
BB Middle1.328 USD
BB Lower0.6491 USD
BB Width102.28%
ATR (14)0.1672 USD
Vol Ratio (20d)0.73x